KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding (Diluted Average): 2010-2024

Historic Shares Outstanding (Diluted Average) for Arbutus Biopharma (ABUS) over the last 14 years, with Dec 2024 value amounting to $185.6 million.

  • Arbutus Biopharma's Shares Outstanding (Diluted Average) rose 1.47% to $191.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.8 million, marking a year-over-year increase of 1.47%. This contributed to the annual value of $185.6 million for FY2024, which is 11.84% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Shares Outstanding (Diluted Average) of $185.6 million as of FY2024, which was up 11.84% from $166.0 million recorded in FY2023.
  • Arbutus Biopharma's 5-year Shares Outstanding (Diluted Average) high stood at $185.6 million for FY2024, and its period low was $75.8 million during FY2020.
  • In the last 3 years, Arbutus Biopharma's Shares Outstanding (Diluted Average) had a median value of $166.0 million in 2023 and averaged $167.5 million.
  • Data for Arbutus Biopharma's Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 42.07% (in 2022) over the last 5 years.
  • Arbutus Biopharma's Shares Outstanding (Diluted Average) (Yearly) stood at $75.8 million in 2020, then spiked by 40.10% to $106.2 million in 2021, then spiked by 42.07% to $150.9 million in 2022, then rose by 9.95% to $166.0 million in 2023, then climbed by 11.84% to $185.6 million in 2024.